BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Monday, May 25, 2026
Home
»
Newsletters
» BioWorld MedTech
BioWorld MedTech
Aug. 5, 2015
View Archived Issues
Drugs enter third dimension: First FDA approval in hand, Aprecia looks to alter drug delivery with 3-D printing
Read More
Less is More with MIS Lipoplasty: Lipoplasty market attractive for both small and large players
Read More
Inside the Beltway: IPPS final rule receives mostly favorable reviews for med-tech DRGs
Read More
Daily M&A: Boston Scientific closes $1.65B buy of the AMS Male Urology Portfolio
Read More
Financings: Novacyt secures flexiblefunding, up to 5 million
Read More
HIT Bits: PhysIQ personalized physiology analytics receives FDA clearance
Read More
People in places
Read More
Products
Read More
MDD's Oncology Extra
Read More
Sour IPO Transforms into Sweet JV: Mevion scraps IPO plans but raises $200M and strikes a JV deal with Chinese investors
A proton therapy systems provider has canceled its plans to go public and now plans to form a joint venture (JV) in China supported by a new investment agreement worth up to $200 million.
Read More
Resmed finds sleeper opportunity: Resmed wakes up to potential of huge Chinese sleep disorder market
Read More
